GBR 1342

Drug Profile

GBR 1342

Alternative Names: BEAT®bsAbs

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen modulators; CD38 antigen modulators; Cytotoxic T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 15 May 2017 US FDA approves IND application for GBR 1342 in Multiple myeloma
  • 15 May 2017 Glenmark Pharmaceuticals plans a phase I trial in Multiple myeloma (Second-line therapy or greater)
  • 08 Jan 2016 Preclinical trials in Multiple myeloma in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top